Medtronic PLC vs Marvell Technology Inc — how do they compare? Medtronic PLC trades at $82.52 (market cap $106.61B), while Marvell Technology Inc trades at $209.57 (market cap $171.11B). The key difference: Marvell Technology Inc is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | MRVL | |
|---|---|---|
Market Cap | $106.61B | $171.11B |
Sector | Health | Technology |
52-Week High | $105.35 | $316.43 |
52-Week Low | $73.75 | $62.31 |
Enterprise Value | $125.36B | $172.55B |
Dividend Yield | 3.46% | 0.12% |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Marvell Technology (MRVL) trades at $195.28, up 3.5% today, with a bullish technical signal from oscillators but bearish moving averages. Recent earnings have consistently beaten expectations, though the company reported a net loss of $885 million in 2025. Analyst consensus is strongly bullish with an average price target of $275.68, and the stock is positioned in the AI infrastructure sector, with news highlighting its potential in custom chips and networking.
Outlook is positive due to strong analyst support and AI-driven growth prospects, but risks include high valuation multiples, recent net losses, and semiconductor market volatility. The stock offers significant upside if execution matches expectations, yet investors must weigh growth potential against current profitability challenges and industry cyclicality.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →